Who Paid My Doc
Melissa Devlin
Critical Care Medicine Great Neck, NY Medical Doctor
NPI 1003078619 CMS profile 45278
891 Northern Blvd, Suite 203, Great Neck, NY 11021
General payments
$135
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Melissa Devlin of Great Neck, NY is reported in the CMS Open Payments database as having received $135 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 28th percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $135 | 1 |
Beside peers
- Melissa Devlin
- Critical Care Medicine median
- Middle half of Critical Care Medicine
- National median
In program year 2025, general payments to Melissa Devlin were reported at $135. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.
Show as a table
| Year | Melissa Devlin | Critical Care Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $149 | $51–$535 | $163 |
| 2020 | $0 | $110 | $30–$325 | $114 |
| 2021 | $0 | $125 | $34–$403 | $132 |
| 2022 | $0 | $157 | $49–$582 | $149 |
| 2023 | $0 | $162 | $56–$621 | $160 |
| 2024 | $0 | $168 | $53–$634 | $164 |
| 2025 | $135 | $189 | $59–$844 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 15 billing codesPaid by Medicare
$82,077
Medicare patients
214
Services billed
750
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 69% | |
| Arthritis | 60% | |
| Diabetes | 56% | |
| COPD | 56% | |
| Heart failure | 51% | |
| Chronic kidney disease | 49% | |
| Atrial fibrillation | 48% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Critical Care Medicine in New York
Joshua Rosenberg
Critical Care Medicine · Brooklyn, NY
Peter Dicpinigaitis
Critical Care Medicine · Bronx, NY
Roxana Sulica
Critical Care Medicine · New York, NY
Boris Shkolnik
Critical Care Medicine · Albany, NY
Paul Strachan
Critical Care Medicine · Melville, NY
Anna Podolanczuk
Critical Care Medicine · New York, NY
Related records
Critical Care Medicine in New York
Practitioners in the same specialty and state, ranked by reported value.
All Critical Care Medicine
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.